RGBP Quote, Financials, Valuation and Earnings

Agenus, Inc. has a net margin of -1637.73% compared to Regen Biopharma, Inc.'s net margin of -31.03%. Regen Biopharma, Inc.'s return on equity of -- beat Agenus, Inc.'s return on equity of --.

Regen Biopharma, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Agenus, Inc. has an analysts' consensus of $15.50 which suggests that it could grow by 270.37%. Given that Agenus, Inc. has higher upside potential than Regen Biopharma, Inc., analysts believe Agenus, Inc. is more attractive than Regen Biopharma, Inc..

Regen Biopharma, Inc. has a beta of 2.846, which suggesting that the stock is 184.602% more volatile than S&P 500. In comparison Agenus, Inc. has a beta of 1.604, suggesting its more volatile than the S&P 500 by 60.406%.

Regen Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Agenus, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Regen Biopharma, Inc. pays -- of its earnings as a dividend. Agenus, Inc. pays out -- of its earnings as a dividend.

Regen Biopharma, Inc. quarterly revenues are $59.1K, which are smaller than Agenus, Inc. quarterly revenues of $34.2M. Regen Biopharma, Inc.'s net income of -$967.9K is higher than Agenus, Inc.'s net income of -$10.6M. Notably, Regen Biopharma, Inc.'s price-to-earnings ratio is -- while Agenus, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regen Biopharma, Inc. is 0.11x versus 0.88x for Agenus, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Curis, Inc. has a net margin of -1637.73% compared to Regen Biopharma, Inc.'s net margin of -243.36%. Regen Biopharma, Inc.'s return on equity of -- beat Curis, Inc.'s return on equity of -461.34%.

Regen Biopharma, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Curis, Inc. has an analysts' consensus of $14.00 which suggests that it could grow by 2445.92%. Given that Curis, Inc. has higher upside potential than Regen Biopharma, Inc., analysts believe Curis, Inc. is more attractive than Regen Biopharma, Inc..

Regen Biopharma, Inc. has a beta of 2.846, which suggesting that the stock is 184.602% more volatile than S&P 500. In comparison Curis, Inc. has a beta of 3.148, suggesting its more volatile than the S&P 500 by 214.753%.

Regen Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Curis, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Regen Biopharma, Inc. pays -- of its earnings as a dividend. Curis, Inc. pays out -- of its earnings as a dividend.

Regen Biopharma, Inc. quarterly revenues are $59.1K, which are smaller than Curis, Inc. quarterly revenues of $1.1M. Regen Biopharma, Inc.'s net income of -$967.9K is lower than Curis, Inc.'s net income of $19.4M. Notably, Regen Biopharma, Inc.'s price-to-earnings ratio is -- while Curis, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regen Biopharma, Inc. is 0.11x versus 0.77x for Curis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Plus Therapeutics, Inc. has a net margin of -1637.73% compared to Regen Biopharma, Inc.'s net margin of -417.92%. Regen Biopharma, Inc.'s return on equity of -- beat Plus Therapeutics, Inc.'s return on equity of --.

Regen Biopharma, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $146.88 which suggests that it could grow by 4025.7%. Given that Plus Therapeutics, Inc. has higher upside potential than Regen Biopharma, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than Regen Biopharma, Inc..

Regen Biopharma, Inc. has a beta of 2.846, which suggesting that the stock is 184.602% more volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 1.025, suggesting its more volatile than the S&P 500 by 2.509%.

Regen Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Regen Biopharma, Inc. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Regen Biopharma, Inc. quarterly revenues are $59.1K, which are smaller than Plus Therapeutics, Inc. quarterly revenues of $1.4M. Regen Biopharma, Inc.'s net income of -$967.9K is higher than Plus Therapeutics, Inc.'s net income of -$5.7M. Notably, Regen Biopharma, Inc.'s price-to-earnings ratio is -- while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regen Biopharma, Inc. is 0.11x versus 3.21x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Windtree Therapeutics, Inc. has a net margin of -1637.73% compared to Regen Biopharma, Inc.'s net margin of --. Regen Biopharma, Inc.'s return on equity of -- beat Windtree Therapeutics, Inc.'s return on equity of -760.4%.

Regen Biopharma, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Windtree Therapeutics, Inc. has an analysts' consensus of $4.0000 which suggests that it could grow by 38734.95%. Given that Windtree Therapeutics, Inc. has higher upside potential than Regen Biopharma, Inc., analysts believe Windtree Therapeutics, Inc. is more attractive than Regen Biopharma, Inc..

Regen Biopharma, Inc. has a beta of 2.846, which suggesting that the stock is 184.602% more volatile than S&P 500. In comparison Windtree Therapeutics, Inc. has a beta of 0.672, suggesting its less volatile than the S&P 500 by 32.828%.

Regen Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Windtree Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Regen Biopharma, Inc. pays -- of its earnings as a dividend. Windtree Therapeutics, Inc. pays out 36.77% of its earnings as a dividend. Windtree Therapeutics, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Regen Biopharma, Inc. quarterly revenues are $59.1K, which are larger than Windtree Therapeutics, Inc. quarterly revenues of --. Regen Biopharma, Inc.'s net income of -$967.9K is higher than Windtree Therapeutics, Inc.'s net income of -$28.1M. Notably, Regen Biopharma, Inc.'s price-to-earnings ratio is -- while Windtree Therapeutics, Inc.'s PE ratio is 0.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regen Biopharma, Inc. is 0.11x versus 0.26x for Windtree Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.